EE200300537A - Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks - Google Patents

Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks

Info

Publication number: EE200300537A
Authority: EE; Estonia
Prior art keywords: manufacture; pharmaceutical composition; low dose; dose pharmaceutical; low
Prior art date: 2001-05-01

Application number

EEP200300537A

Other languages

English (en)

Inventor

Scott Gierer Daniel

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-01

Filing date

2002-03-13

Publication date

2004-04-15

2002-03-13 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-04-15 Publication of EE200300537A publication Critical patent/EE200300537A/et

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EEP200300537A 2001-05-01 2002-03-13 Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks EE200300537A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28784101P	2001-05-01	2001-05-01
PCT/IB2002/000766 WO2002087546A2 (en)	2001-05-01	2002-03-13	Method for manufacturing a low dose pharmaceutical composition

Publications (1)

Publication Number	Publication Date
EE200300537A true EE200300537A (et)	2004-04-15

Family

ID=23104578

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300537A EE200300537A (et)	2001-05-01	2002-03-13	Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks

Country Status (43)

Country	Link
US (2)	US7037530B2 (et)
EP (1)	EP1383482B1 (et)
JP (1)	JP2004531537A (et)
KR (1)	KR100568380B1 (et)
CN (1)	CN1240375C (et)
AP (1)	AP2003002900A0 (et)
AR (1)	AR033288A1 (et)
AT (1)	ATE367152T1 (et)
AU (1)	AU2002236166B2 (et)
BG (1)	BG108297A (et)
BR (1)	BR0209283A (et)
CA (1)	CA2445519C (et)
CZ (1)	CZ20032959A3 (et)
DE (1)	DE60221238T2 (et)
DK (1)	DK1383482T3 (et)
DO (1)	DOP2002000389A (et)
EA (1)	EA005949B1 (et)
EC (1)	ECSP034826A (et)
EE (1)	EE200300537A (et)
ES (1)	ES2286226T3 (et)
GE (1)	GEP20053654B (et)
GT (1)	GT200200078A (et)
HR (1)	HRP20030858A2 (et)
HU (1)	HUP0401391A3 (et)
IL (1)	IL158390A0 (et)
IS (1)	IS6985A (et)
MA (1)	MA27017A1 (et)
MX (1)	MXPA03009391A (et)
NO (1)	NO20034709L (et)
NZ (1)	NZ528886A (et)
OA (1)	OA12596A (et)
PA (1)	PA8544401A1 (et)
PE (1)	PE20021137A1 (et)
PL (1)	PL366453A1 (et)
PT (1)	PT1383482E (et)
SK (1)	SK286536B6 (et)
TN (1)	TNSN03106A1 (et)
TW (1)	TWI264311B (et)
UA (1)	UA75135C2 (et)
UY (1)	UY27277A1 (et)
WO (1)	WO2002087546A2 (et)
YU (1)	YU81503A (et)
ZA (1)	ZA200307819B (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003082814A1 (en)	2002-03-28	2003-10-09	Pfizer Products Inc.	Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7444197B2 (en)	2004-05-06	2008-10-28	Smp Logic Systems Llc	Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en)	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
CN101448407A (zh) *	2006-05-17	2009-06-03	Wm.雷格利Jr.公司	制备食物产品的方法
FI20080351A0 (fi) *	2008-05-09	2008-05-09	Atacama Labs Oy	Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
FI20070521A7 (fi)	2006-11-10	2008-05-11	Atacama Labs Oy	Rakeita, tabletteja ja rakeistusmenetelmä
US8951562B2 (en)	2006-11-10	2015-02-10	Atacama Labs Oy	Method and apparatus or dry granulation
AU2007335155A1 (en) *	2006-12-20	2008-06-26	Mylan Pharmaceuticals Ulc	A composition containing a bisphosphonic acid in combination with vitamin D
US20080181972A1 (en) *	2007-01-29	2008-07-31	Valentina Amico	Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
DK2487166T3 (en)	2007-02-23	2017-02-20	Gilead Sciences Inc	Modulators of the pharmacokinetic properties of therapeutics
ES2553897T3 (es)	2008-05-02	2015-12-14	Gilead Sciences, Inc.	El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
EP2291233B1 (en) *	2008-05-09	2019-09-04	Atacama Labs Oy	Method for dry granulation
US20170065529A1 (en)	2015-09-09	2017-03-09	Boehringer Ingelheim International Gmbh	Pharmaceutical dosage form for immediate release of an indolinone derivative
PE20100254A1 (es) *	2008-06-06	2010-04-21	Boehringer Ingelheim Int	Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
WO2010094535A1 (en) *	2009-01-29	2010-08-26	Ucb Pharma, S.A.	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
PL2391351T3 (pl) *	2009-01-29	2015-02-27	Ucb Pharma Sa	Kompozycje farmaceutyczne zawierające pochodne 2-okso-1-pirolidyny
US20140350945A1 (en) *	2013-05-22	2014-11-27	Professional Compounding Centers Of America	System and Method for Validation of Pharmaceutical Composition Formulations
CN103830196A (zh) *	2014-03-14	2014-06-04	王志刚	一种酒石酸拉索昔芬分散片及其制备方法
CN106176649B (zh) *	2016-08-31	2020-04-17	北京斯利安药业有限公司	叶酸vb12片及其制备方法
BR112019015904A2 (pt) *	2017-02-17	2020-03-24	Massachusetts Institute Of Technology	Sistemas e métodos para a fabricação de comprimidos, incluindo comprimidos farmacêuticos
CZ309820B6 (cs) *	2021-04-23	2023-11-08	Pro.Med.Cs Praha A.S.	Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky
CN117530926A (zh)	2022-08-02	2024-02-09	江苏众红生物工程创药研究院有限公司	一种舌下片及其在脱敏治疗药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3725555A (en) *	1967-08-01	1973-04-03	Ciba Geigy Corp	Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates
US3725556A (en)	1970-11-12	1973-04-03	D Hanssen	Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4013785A (en)	1975-03-21	1977-03-22	Bristol-Myers Company	Apap tablet containing fumed silica and process for manufacturing same
GB1570993A (en) *	1976-05-21	1980-07-09	Fisons Ltd	Pharmaceutical tablet formulation
DE2845326C2 (de)	1978-10-18	1985-05-23	Beiersdorf Ag, 2000 Hamburg	Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4489026A (en)	1982-09-07	1984-12-18	The Upjohn Company	Process for preparing solid unit dosage forms of ultra-low dose drugs
US5004613A (en)	1987-07-27	1991-04-02	Mcneil-Ppc, Inc.	Oral sustained release pharmaceutical formulation and process
US5047246A (en)	1988-09-09	1991-09-10	Bristol-Myers Company	Direct compression cyclophosphamide tablet
US5107331A (en) *	1989-03-07	1992-04-21	The Color Group	Method and apparatus for producing half-tone separations at the same screen angle
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IE67345B1 (en) *	1991-03-12	1996-03-20	Akzo Nv	Low dose dry pharmaceutical preparations
US5464632C1 (en)	1991-07-22	2001-02-20	Prographarm Lab	Rapidly disintegratable multiparticular tablet
US5358941A (en)	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
US5976570A (en)	1993-12-21	1999-11-02	Applied Analytical Industries, Inc.	Method for preparing low dose pharmaceutical products
US5928668A (en)	1993-12-21	1999-07-27	Applied Analytical Industries, Inc.	Method for dry blend compression of medicaments
ES2082723B1 (es)	1994-07-20	1996-10-01	Lilly Sa	Formulacion farmaceutica de fluoxetina en forma dispersable.
US5478572A (en) *	1994-09-06	1995-12-26	Bristol-Myers Squibb Co.	Gepirone dosage form
ES2079327B1 (es)	1994-12-13	1996-08-01	Lilly Sa	Formulaciones farmaceuticas de cefaclor.
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
GB9501127D0 (en)	1995-01-20	1995-03-08	Wellcome Found	Tablet
US5726168A (en) *	1995-10-12	1998-03-10	Eli Lilly And Company	Lipophilic benzothiophenes
UA51676C2 (uk) *	1995-11-02	2002-12-16	Пфайзер Інк.	(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
US5733578A (en)	1995-11-15	1998-03-31	Edward Mendell Co., Inc.	Directly compressible high load acetaminophen formulations
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5916916A (en) *	1996-10-10	1999-06-29	Eli Lilly And Company	1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2218756A1 (en) *	1996-10-25	1998-04-25	Kristin Sue Marron	Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
US6080427A (en)	1997-04-17	2000-06-27	Bristol-Myers Squibb Company	Cefadroxil monohydrate tablet formulation
PT889056E (pt)	1997-07-01	2006-07-31	Pfizer Prod Inc	Processo para produzir um,a ciclodextrina.
US6300367B1 (en) *	1999-04-20	2001-10-09	Protein Technologies International, Inc.	Composition for and method of preventing or treating breast cancer
US6555551B1 (en) *	1999-08-31	2003-04-29	Mutual Pharmaceutical Co., Inc.	Stable formulations of ACE inhibitors, and methods for preparation thereof
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos

2002
- 2002-03-13 DE DE60221238T patent/DE60221238T2/de not_active Expired - Fee Related
- 2002-03-13 EA EA200301040A patent/EA005949B1/ru not_active IP Right Cessation
- 2002-03-13 CZ CZ20032959A patent/CZ20032959A3/cs unknown
- 2002-03-13 ES ES02702671T patent/ES2286226T3/es not_active Expired - Lifetime
- 2002-03-13 KR KR1020037014223A patent/KR100568380B1/ko not_active Expired - Fee Related
- 2002-03-13 AP APAP/P/2003/002900A patent/AP2003002900A0/en unknown
- 2002-03-13 HU HU0401391A patent/HUP0401391A3/hu unknown
- 2002-03-13 AT AT02702671T patent/ATE367152T1/de not_active IP Right Cessation
- 2002-03-13 EP EP02702671A patent/EP1383482B1/en not_active Expired - Lifetime
- 2002-03-13 WO PCT/IB2002/000766 patent/WO2002087546A2/en not_active Ceased
- 2002-03-13 EE EEP200300537A patent/EE200300537A/et unknown
- 2002-03-13 OA OA1200300274A patent/OA12596A/en unknown
- 2002-03-13 IL IL15839002A patent/IL158390A0/xx unknown
- 2002-03-13 HR HR20030858A patent/HRP20030858A2/xx not_active Application Discontinuation
- 2002-03-13 MX MXPA03009391A patent/MXPA03009391A/es active IP Right Grant
- 2002-03-13 UA UA2003109816A patent/UA75135C2/uk unknown
- 2002-03-13 NZ NZ528886A patent/NZ528886A/en unknown
- 2002-03-13 DK DK02702671T patent/DK1383482T3/da active
- 2002-03-13 CN CNB028092554A patent/CN1240375C/zh not_active Expired - Fee Related
- 2002-03-13 PL PL02366453A patent/PL366453A1/xx not_active Application Discontinuation
- 2002-03-13 BR BR0209283-2A patent/BR0209283A/pt not_active IP Right Cessation
- 2002-03-13 GE GE5339A patent/GEP20053654B/en unknown
- 2002-03-13 PT PT02702671T patent/PT1383482E/pt unknown
- 2002-03-13 CA CA002445519A patent/CA2445519C/en not_active Expired - Fee Related
- 2002-03-13 AU AU2002236166A patent/AU2002236166B2/en not_active Ceased
- 2002-03-13 SK SK1355-2003A patent/SK286536B6/sk not_active IP Right Cessation
- 2002-03-13 JP JP2002584892A patent/JP2004531537A/ja not_active Ceased
- 2002-03-13 YU YUP-815/03A patent/YU81503A/sh unknown
- 2002-04-23 US US10/131,556 patent/US7037530B2/en not_active Expired - Fee Related
- 2002-04-25 TW TW091108572A patent/TWI264311B/zh not_active IP Right Cessation
- 2002-04-26 DO DO2002000389A patent/DOP2002000389A/es unknown
- 2002-04-29 PA PA20028544401A patent/PA8544401A1/es unknown
- 2002-04-29 GT GT200200078A patent/GT200200078A/es unknown
- 2002-04-29 AR ARP020101574A patent/AR033288A1/es unknown
- 2002-04-30 UY UY27277A patent/UY27277A1/es not_active Application Discontinuation
- 2002-04-30 PE PE2002000368A patent/PE20021137A1/es not_active Application Discontinuation
2003
- 2003-07-08 TN TNPCT/IB2002/000766A patent/TNSN03106A1/fr unknown
- 2003-10-07 ZA ZA200307819A patent/ZA200307819B/en unknown
- 2003-10-09 IS IS6985A patent/IS6985A/is unknown
- 2003-10-21 NO NO20034709A patent/NO20034709L/no not_active Application Discontinuation
- 2003-10-28 MA MA27375A patent/MA27017A1/fr unknown
- 2003-10-28 BG BG108297A patent/BG108297A/bg unknown
- 2003-10-31 EC EC2003004826A patent/ECSP034826A/es unknown
2005
- 2005-12-13 US US11/302,894 patent/US7176221B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE367152T1 (de)	2007-08-15
AU2002236166B2 (en)	2006-12-07
YU81503A (sh)	2006-08-17
KR100568380B1 (ko)	2006-04-05
MA27017A1 (fr)	2004-12-20
UA75135C2 (en)	2006-03-15
CN1240375C (zh)	2006-02-08
NO20034709L (no)	2003-10-31
PT1383482E (pt)	2007-09-20
HUP0401391A2 (hu)	2004-12-28
JP2004531537A (ja)	2004-10-14
AR033288A1 (es)	2003-12-10
EP1383482A2 (en)	2004-01-28
GEP20053654B (en)	2005-11-10
US20060093667A1 (en)	2006-05-04
TWI264311B (en)	2006-10-21
SK286536B6 (sk)	2008-12-05
ZA200307819B (en)	2004-10-07
OA12596A (en)	2006-06-08
WO2002087546A2 (en)	2002-11-07
UY27277A1 (es)	2002-11-29
US20030004182A1 (en)	2003-01-02
BR0209283A (pt)	2004-07-13
WO2002087546A3 (en)	2003-02-13
US7176221B2 (en)	2007-02-13
US7037530B2 (en)	2006-05-02
PA8544401A1 (es)	2003-07-28
ES2286226T3 (es)	2007-12-01
IS6985A (is)	2003-10-09
CN1531423A (zh)	2004-09-22
IL158390A0 (en)	2004-05-12
EP1383482B1 (en)	2007-07-18
CA2445519A1 (en)	2002-11-07
PL366453A1 (en)	2005-02-07
HRP20030858A2 (en)	2005-08-31
EA005949B1 (ru)	2005-08-25
NZ528886A (en)	2005-04-29
CZ20032959A3 (cs)	2004-01-14
HK1065705A1 (en)	2005-03-04
BG108297A (bg)	2005-07-29
ECSP034826A (es)	2004-02-26
TNSN03106A1 (fr)	2005-12-23
GT200200078A (es)	2003-01-31
MXPA03009391A (es)	2004-01-29
EA200301040A1 (ru)	2004-04-29
DK1383482T3 (da)	2007-10-29
AP2003002900A0 (en)	2003-12-31
NO20034709D0 (no)	2003-10-21
KR20040015226A (ko)	2004-02-18
CA2445519C (en)	2009-01-20
DE60221238T2 (de)	2007-10-31
DOP2002000389A (es)	2002-11-30
PE20021137A1 (es)	2002-12-14
HUP0401391A3 (en)	2009-06-29
DE60221238D1 (de)	2007-08-30
SK13552003A3 (sk)	2004-09-08

Publication	Publication Date	Title
EE200300537A (et)	2004-04-15	Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
FI20011478L (fi)	2003-01-06	Farmaseuttinen koostumus
GB0117618D0 (en)	2001-09-12	Pharmaceutical dosage form
DK1420759T3 (da)	2009-08-03	Farmaceutiske sammensætninger til behandling af astma
SI1390023T1 (sl)	2008-10-31	Farmacevtske soli spojin 1-fenil-3-dimetilamino-propana
EE200300416A (et)	2003-12-15	Ravimvorm
GB0117619D0 (en)	2001-09-12	Pharmaceutical dosage form
EE05020B1 (et)	2008-06-16	Glburiidi ravimkoostis
EP1425019A4 (en)	2004-11-17	PHARMACEUTICAL COMPOSITION
DK1349580T3 (da)	2007-10-01	Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning
IS7051A (is)	2003-11-26	Lyfjasamsetningar
AU2002341241A1 (en)	2003-04-07	Process for the preparation of fast dissolving dosage form
FI20022128A7 (fi)	2003-06-06	Farmaseuttinen koostumus
ATE324883T1 (de)	2006-06-15	Pharmazeutische zusammensetzung enthaltend lumiracoxib
DK1443938T3 (da)	2011-09-26	Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse
NO20034556L (no)	2003-12-10	Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60217390D1 (de)	2007-02-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
IS7219A (is)	2004-04-14	Lyfjablanda sem inniheldur (R) -bíkalútamíð
DK1446107T3 (da)	2014-11-03	Fremgangsmåde til fremstilling af tabletter omfattende s-adenosylmethionin
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
IS6857A (is)	2003-06-23	Lyfjafræðileg samsetning sem innheldur sítalópram
FI20010892A0 (fi)	2001-04-27	Menetelmä ksylitolin valmistamiseksi
FI20012242A0 (fi)	2001-11-19	Uudet farmaseuttiset yhdisteet
EE200300378A (et)	2003-10-15	Farmatseutiline kompositsioon